Fixed-combination and emerging glaucoma therapies
作者： David F Woodward , June Chen
DOI: 10.1517/14728214.12.2.313
关键词: Bimatoprost 、 Pharmacotherapy 、 Brimonidine 、 Ophthalmology 、 Dorzolamide 、 Glaucoma 、 Intensive care medicine 、 Travoprost 、 Timolol 、 Medicine 、 Latanoprost 、 Pharmacology (medical) 、 Pharmacology
摘要: Ocular hypotensive agents are the only approved pharmacotherapy for glaucoma. Despite significant advances during past two decades, a large proportion of glaucoma patients require more than one drug. The most recent additions to armamentarium antiglaucoma drugs fixed-combination products patient who is insufficiently responsive monotherapy. Fixed-combination have combined efficacy ocular drugs, and convenience two-drug treatment regimen in single container, which may aid adherence treatment. Available consist timolol 0.5% as an invariant with brimonidine 0.2%, dorzolamide 2%, travoprost 0.004%, latanoprost 0.005% or bimatoprost 0.03%. Research on advanced medications continues. Promising new directions appear be Rho-kinase inhibitors, microtubule-disrupting agents, serotonergics cannabimimetics. Efforts continue improve existing att...
informapharmascience.com参考文章(68)
Essy Mozaffari, Tara R. Cockerham, Michael F. Bullano, Thomas Johnson, William J. Waugh, Joshua J. Spooner, Laurence I. Ikeda, Rates of Discontinuation and Change of Glaucoma Therapy in a Managed Care Setting The American Journal of Managed Care. ,vol. 8, ,(2002)
Shaya Ft, Cho J, Mullins Cd, Wong W, Discontinuation rates of topical glaucoma medications in a managed care population. The American Journal of Managed Care. ,vol. 8, ,(2002)
Essy Mozaffari, Gail F Schwartz, Samaresh Dasgupta, Brahim K Bookhart, Baze Vaziri, Vikki Oates, Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. The American Journal of Managed Care. ,vol. 8, ,(2002)
M. Holoboski, M. Posner, A.H. Krauss, J. Chen, T. Dinh, A.L. Nieves, D.F. Woodward, A.B. Kharlamb, R.M. Burk, S.F. E. Nilsson, PROSTANOID EP4 RECEPTOR STIMULATION PRODUCES PROFOUND OCULAR HYPOTENSION THAT INVOLVES PRESSURE DEPENDENT OUTFLOW Investigative Ophthalmology & Visual Science. ,vol. 45, pp. 1035- 1035 ,(2004)
M. Holoboski, M. Posner, D.F. Woodward, A.B. Kharlamb, R.M. Burk, Ciliary Muscle Relaxation Does Not Explain the Profound Ocular Hypotension Produced by a Selective Prostanoid EP4 Receptor Agonist 3,7–Dithia PGE1 in Monkeys Investigative Ophthalmology & Visual Science. ,vol. 47, pp. 413- 413 ,(2006)
Johan Wilhelm Stjernschantz, From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Investigative Ophthalmology & Visual Science. ,vol. 42, pp. 1134- 1145 ,(2001)
Shuh Narumiya, Tatsuya Sawamura, Hidenobu Tanihara, Beatrice Y. J. T. Yue, Yoshihito Honda, Megumi Honjo, Noriaki Kido, Masaru Inatani, Effects of Rho-Associated Protein Kinase Inhibitor Y-27632 on Intraocular Pressure and Outflow Facility Investigative Ophthalmology & Visual Science. ,vol. 42, pp. 137- 144 ,(2001)
Richard F Brubaker, Erik O Schoff, Cherie B Nau, Susan P Carpenter, Kuankuan Chen, Amanda M Vandenburgh, Effects of AGN 192024, a New Ocular Hypotensive Agent, on Aqueous Dynamics American Journal of Ophthalmology. ,vol. 131, pp. 19- 24 ,(2001) , 10.1016/S0002-9394(00)00843-6
Sarah A. Taylor, Sharon M. Galbraith, Richard P. Mills, Causes Of Non-Compliance With Drug Regimens In Glaucoma Patients: A Qualitative Study Journal of Ocular Pharmacology and Therapeutics. ,vol. 18, pp. 401- 409 ,(2002) , 10.1089/10807680260362687
D.F Woodward, A.H.-P Krauss, J Chen, R.K Lai, C.S Spada, R.M Burk, S.W Andrews, L Shi, Y Liang, K.M Kedzie, R Chen, D.W Gil, A Kharlamb, A Archeampong, J Ling, C Madhu, J Ni, P Rix, J Usansky, H Usansky, A Weber, D Welty, W Yang, D.D.-S Tang-Liu, M.E Garst, B Brar, L.A Wheeler, L.J Kaplan, The pharmacology of bimatoprost (Lumigan). Survey of Ophthalmology. ,vol. 45, ,(2001) , 10.1016/S0039-6257(01)00224-7